US Patent 11160800 Methods of treatment using a JAK inhibitor compound

Patent 11160800 was granted and assigned to Theravance on November, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Theravance

Current Assignee

Theravance

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11160800

Date of Patent

November 2, 2021

Patent Application Number

20191218

Date Filed

December 18, 2019

Patent Citations Received

‌

US Patent 11667637 Fused imidazo-piperidine JAK inhibitors

Patent abstract

The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11160800 Methods of treatment using a JAK inhibitor compound

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API